Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Caitlin B Conboy

Showing results (21-30 of 26) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 26 results.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaHendrien Kuipers, Danielle M Carlson, Erik Jessen, et al.
Hepatology Communications|November 9, 2019
R-spondin 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent MannerCaitlin B Conboy, Germán L Vélez-Reyes, Barbara R Tschida, et al.
Cancer Discovery|March 29, 2013
Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenanceAdrienne L Watson, Eric P Rahrmann, Branden S Moriarity, et al.
Journal of Hepatology|September 26, 2022
LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinomaCaitlin B Conboy, Jennifer A Yonkus, EeeLN H Buckarma, et al.
Nature|August 17, 2012
Recurrent R-spondin fusions in colon cancerSomasekar Seshagiri, Eric W Stawiski, Steffen Durinck, et al.
The Oncologist|September 19, 2025
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective studyIoannis Kournoutas, Paulina Marell, Jennifer Gile, et al.
Pageof 3

Showing results (21-30 of 26) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 26 results.
Biorxiv : the Preprint Server for Biology|February 6, 2026
Multiomics-driven discovery of predictive biomarkers and strategies to overcome resistance to SFK-YAP inhibition in cholangiocarcinomaHendrien Kuipers, Danielle M Carlson, Erik Jessen, et al.
Hepatology Communications|November 9, 2019
R-spondin 2 Drives Liver Tumor Development in a Yes-Associated Protein-Dependent MannerCaitlin B Conboy, Germán L Vélez-Reyes, Barbara R Tschida, et al.
Cancer Discovery|March 29, 2013
Canonical Wnt/β-catenin signaling drives human schwann cell transformation, progression, and tumor maintenanceAdrienne L Watson, Eric P Rahrmann, Branden S Moriarity, et al.
Journal of Hepatology|September 26, 2022
LCK inhibition downregulates YAP activity and is therapeutic in patient-derived models of cholangiocarcinomaCaitlin B Conboy, Jennifer A Yonkus, EeeLN H Buckarma, et al.
Nature|August 17, 2012
Recurrent R-spondin fusions in colon cancerSomasekar Seshagiri, Eric W Stawiski, Steffen Durinck, et al.
The Oncologist|September 19, 2025
First-line atezolizumab/bevacizumab or durvalumab/tremelimumab in advanced hepatocellular carcinoma: a real world, multicenter retrospective studyIoannis Kournoutas, Paulina Marell, Jennifer Gile, et al.
Pageof 3